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Circulating adiponectin levels are lower in Latino
versus non-Latino white patients at risk for
cardiovascular disease, independent of adiposity
measures
Rocio I Pereira1,2*, Cecilia CL Wang2,3, Patrick Hosokawa2, L Miriam Dickinson2, Michel Chonchol2, Mori J Krantz1,
John F Steiner4, Daniel H Bessesen1,2, Edward P Havranek1 and Carlin S Long1
Abstract
Background: Latinos in the United States have a higher prevalence of type 2 diabetes than non-Latino whites,
even after controlling for adiposity. Decreased adiponectin is associated with insulin resistance and predicts T2DM,
and therefore may mediate this ethnic difference. We compared total and high-molecular-weight (HMW)
adiponectin in Latino versus white individuals, identified factors associated with adiponectin in each ethnic group,
and measured the contribution of adiponectin to ethnic differences in insulin resistance.
Methods: We utilized cross-sectional data from subjects in the Latinos Using Cardio Health Actions to reduce Risk
study. Participants were Latino (n = 119) and non-Latino white (n = 60) men and women with hypertension and at
least one other risk factor for CVD (age 61 ± 10 yrs, 49% with T2DM), seen at an integrated community health and
hospital system in Denver, Colorado. Total and HMW adiponectin was measured by RIA and ELISA respectively.
Fasting glucose and insulin were used to calculate the homeostasis model insulin resistance index (HOMA-IR).
Variables independently associated with adiponectin levels were identified by linear regression analyses.
Adiponectin’s contribution to ethnic differences in insulin resistance was assessed in multivariate linear regression
models of Latino ethnicity, with logHOMA-IR as a dependent variable, adjusting for possible confounders including
age, gender, adiposity, and renal function.
Results: Mean adiponectin levels were lower in Latino than white patients (beta estimates: -4.5 (-6.4, -2.5), p <
0.001 and -1.6 (-2.7, -0.5), p < 0.005 for total and HMW adiponectin), independent of age, gender, BMI/waist
circumference, thiazolidinedione use, diabetes status, and renal function. An expected negative association
between adiponectin and waist circumference was seen among women and non-Latino white men, but no
relationship between these two variables was observed among Latino men. Ethnic differences in logHOMA-IR were
no longer observed after controlling for adiponectin levels.
Conclusions: Among patients with CVD risk, total and HMW adiponectin is lower in Latinos, independent of
adiposity and other known regulators of adiponectin. Ethnic differences in adiponectin regulation may exist and
future research in this area is warranted. Adiponectin levels accounted for the observed variability in insulin
resistance, suggesting a contribution of decreased adiponectin to insulin resistance in Latino populations.
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Background
Latinos in the United States have a higher incidence and
prevalence of insulin resistance, and consequently type 2
diabetes mellitus [1,2], compared to non-Latino whites.
Though this observation has been attributed, at least in
part, to a higher rate of obesity in Latinos [1], insulin
resistance and type 2 diabetes are more prevalent in
Latinos compared to whites even after controlling for
weight differences [1,3-5].
Adiponectin, a circulating protein made primarily by
adipose tissue [6-9], has been identified as a mediator of
whole body insulin sensitivity [10-12]. Adiponectin levels
are positively correlated with insulin sensitivity [13], and
decreased levels of adiponectin are observed in insulin-
resistant conditions [13,14] including type 2 diabetes
mellitus. Adiponectin administration in animal models
[12], and therapeutic interventions that increase adipo-
nectin in humans such as anti-diabetic agents in the thia-
zolidinedione (TZD) class, are associated with improved
insulin sensitivity [15,16]. Furthermore, decreased adipo-
nectin levels precede decreases in whole body insulin
sensitivity in humans [14], supporting a role for adipo-
nectin as a mediator of insulin sensitivity. Though much
research has been done on adiponectin, regulation of adi-
ponectin levels remains poorly understood. Adiponectin
levels have been predominantly associated with measures
of adiposity [13,17] but are also associated with age [18],
gender [19], presence of diabetes [20], renal function [21]
and TZD use [22]. Associations with other factors includ-
ing use of angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin receptor blockers (ARB) [23], acet-
ylsalicylic acid [24], and statins [25] remain controversial.
Racial minorities (Black, American Indian, and Asian)
have been reported to have lower circulating adiponectin
levels compared to white individuals [5,26-28]. However,
we are aware of only one previous report of decreased adi-
ponectin levels in Latinos compared to non-Latino whites
[5], and studies identifying determinants of adiponectin
levels in Latinos or exploring the contribution of decreased
adiponectin to decreased insulin sensitivity in this popula-
tion are lacking. Furthermore, no information is currently
available on ethnic differences in high-molecular-weight
(HMW) adiponectin, which is thought to be the active
form of the hormone.
In the present analysis we compared total and HMW
adiponectin levels in a heterogeneous population of Latino
(mostly Mexican-American) and non-Latino white
patients with chronic hypertension, and measured the
independent association between adiponectin levels and
ethnicity. We identified determinants of adiponectin levels
and explored the relationship between adiponectin and
adiposity (BMI and waist circumference) in each ethnic
group and in the population as a whole. Lastly, we
assessed the contribution of decreased adiponectin levels
to ethnic differences in HOMA-IR (a surrogate marker of
insulin resistance) independent of other known predictors
of insulin resistance.
Methods
Participants
Subjects in the Latinos Using Cardio Health Actions to
Reduce Risk (LUCHAR) study were included in this
cross-sectional study. The overall aim of LUCHAR is to
improve cardiovascular disease (CVD) prevention in Lati-
nos, taking into account a higher prevalence of cardiovas-
cular risk factors, lower treatment rates, and unique
social, cultural, language, and access-to-care barriers
when compared to non-Latino white patients. The
LUCHAR cohort included in the present study was
recruited to investigate surrogate markers of CVD in
Latinos. Laboratory measures specific to the present
study were measured from stored blood samples obtained
from the LUCHAR project. The study protocol was
approved by the Colorado Multiple Institutional Review
Board (COMIRB) and written consent was obtained from
all participants. All study procedures were conducted
according to the principles expressed in the Declaration
of Helsinki. The study was conducted at Denver Health
Medical Center (DHMC), an integrated community
health and safety-net hospital system in Denver, Color-
ado, United States of America. Potential subjects were
identified using the DHMC electronic hypertension regis-
try comprised of patients with at least one diagnostic
(ICD-9) code for hypertension, seen in the DHMC sys-
tem between July 1, 2002 and June 30, 2007. Health
information, including past medical history and medica-
tion use, were obtained from an initial chart review and
from patient self-report. Patients were eligible for the
study if they had a prior diagnosis of hypertension, were
≥18 years of age, attended a clinic in the DHMC system,
and were of either self-reported Latino or non-Latino
white race/ethnicity. Subjects were also required to have
self-reported history or diagnosis of at least one other
cardiovascular risk factor including diabetes, dyslipide-
mia, obesity, chronic kidney disease/microalbuminuria,
current smoking, or older age (men >55 years, women
>65 years). Patients were excluded if they had a known
history of cardiovascular disease (myocardial infarction
or coronary revascularization), history of stroke, cerebro-
vascular revascularization, peripheral arterial disease,
chronic heart failure, valvular heart disease, end-stage
renal disease, inflammatory disease or vasculitis. Eligible
participants were contacted via telephone and invited to
schedule a study visit. All individuals meeting eligibility
criteria and consenting to participate in the study were
included in the LUCHAR cohort. Subject recruitment
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was continued until the predetermined number of parti-
cipants needed for the analyses of CVD outcomes was
achieved. All 179 subjects in the final LUCHAR cohort
were included in the present analysis.
Protocol
Eligible participants were contacted via telephone and
scheduled for a study visit. Participants were asked to fast
for the 8 hours prior to their study visit. At the study visit,
subjects completed a personal history questionnaire and
reviewed a list of current medications. Height, weight,
waist circumference, and blood pressure were measured.
Fasting blood samples were drawn for basic chemistry
panel, fasting lipids, complete blood count, HbA1c, and
high sensitivity C-reactive protein (hsCRP). Insulin, total
adiponectin, and HMW adiponectin were measured from
stored plasma samples from this study visit.
Laboratory Assays
Insulin and total adiponectin were measured by RIA
(Diagnostic Systems Laboratory, Inc., Webster, TX; and
LINCO Research, Inc.; St. Charles, MO respectively).
Intra-assay precision for the total adiponectin assay is
1.78-3.59% CV, and inter-assay precision is 6.90-9.25%
CV. HMW adiponectin was measured by ELISA (Milli-
pore, Billerica, MA); intra-assay precision is 2.5-4.7% CV
and inter-assay precision is 5.8-6.9% CV. All other labs
were measured by the Denver Health Core Laboratory
using standard procedures.
Calculations
The homeostasis model insulin resistance index [29] was
calculated from fasting insulin and glucose levels using the
formula: HOMA-IR = (fasting insulin in mU/l × (fasting
plasma glucose in mg/dl)/18))/22.5. Body mass index
(BMI) was calculated as weight divided by squared height.
Estimated GFR (eGFR) was calculated using the 4-variable
abbreviated MDRD formula [30]: eGFR = 186 × (serum
creatinine)-1.154 × (age)-0.203 × (0.742 if female) × (1.210 if
black).
Statistical Analyses
SAS version 9.2 (SAS Institute, Inc., Cary, NC) was used
for all statistical analyses. Means, medians, and standard
deviations were generated for each variable, stratified by
gender and ethnicity. Group differences were assessed by
Students t-test. Wilcoxon’s test was used for non-normally
distributed variables. A two-sided p value < 0.05 was con-
sidered statistically significant. Kendall’s Tau bivariate ana-
lyses were performed between total or HMW adiponectin
and variables thought likely to predict adiponectin level,
both within each ethnic group and in the entire popula-
tion. In addition to known associates of adiponectin levels
including age, gender, BMI, waist circumference, diagnosis
of diabetes, renal function, and use of TZD, we included
use of medications associated with adiponectin in other
populations (ACEI and ARB, acetylsalicylic acid, and sta-
tins) as exploratory variables. The correlation between
total adiponectin and HMW adiponectin was also mea-
sured in order to verify an expected association between
these two variables.
To identify independent determinants of adiponectin,
multivariate linear regression analyses were performed
with total or HMW adiponectin as the dependent variable.
An interaction term for ethnicity x waist circumference
was used to assess a possible moderating effect of waist
circumference on the relationship between ethnicity and
adiponectin.
We measured adiponectin’s contribution to the
observed ethnic difference in insulin resistance by per-
forming multivariate regression analyses with logarith-
mically transformed HOMA-IR as the outcome variable.
Initially, ethnicity, confounders (age, gender, TZD use,
Statin use, estimated GFR, and diabetes status), and
either BMI or waist circumference were entered into the
model. Next, total adiponectin was added to each
model. Finally, HMW adiponectin was substituted for
total adiponectin.
Results
Subject characteristics
Clinical and biochemical characteristics are shown in
Table 1, stratified by ethnicity and gender. Our subject
cohort was made up of 119 Latinos (81 women, 38 men)
and 60 non-Latino whites (39 women, 21 men). Though
individuals from any Latino sub-group were eligible to
participate, >97% of participants in the Latino cohort were
of Mexican-American descent, reflective of the make-up
of the Latino population in the Denver area. Average age
was 61.4 +/- 9.7 years and mean BMI was 33.1 +/- 6.7 kg/
m2. Overall, 49% of subjects had type 2 diabetes. There
were no ethnic group differences in BMI, but mean waist
circumference was lower in the Latina women compared
to the white women. White women had lower mean esti-
mated GFR than Latina women, but mean eGFR was
within the normal range for all groups. In regards to medi-
cation use, TZD use was higher and ASA use was lower in
Latino men compared to white men, but use of ACEI/
ARB and statin was not different in the two ethnic groups.
No ethnic group differences were observed in other demo-
graphic or clinical characteristics (age, gender representa-
tion, fasting lipids, systolic blood pressure, or hs-CRP).
Decreased total and HMW adiponectin in Latinos
Median total and HMW adiponectin was lower in Latinos
compared to non-Latino whites (Table 1 and figure 1).
Total adiponectin in Latinos and non-Latinos was 7.0 (4.9-
11.4) versus 11.4 (7.3-17.1) μg/ml in women, p = 0.001
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and 4.6 (3.8-6.5) versus 6.0 (5.0-10.6) μg/ml in men, p =
0.02 (figure 1). Similarly, HMW adiponectin was lower in
the Latino versus non-Latino group (2.8 (1.7-5.0) versus
4.4 (2.8-7.9) μg/ml in women, p = 0.009 and 2.3 (1.2-3.7)
versus 2.9 (2.0-3.9) μg/ml in men, p = 0.1). HMW/total
adiponectin ratio was not different between the two
groups.
Correlates of adiponectin
In order to identify additional correlates of adiponectin
levels, bivariate associations between total or HMW adi-
ponectin and variables thought likely to influence adipo-
nectin levels were assessed (Table 2). Strength and
magnitude of correlations with total and HMW adipo-
nectin were similar, and an expected strong association
between total and HMW adiponectin was observed.
Older age, and female gender, were positively associated
with adiponectin levels in both ethnic groups. TZD use
was significantly associated with adiponectin in the
Latino group only. ACEI/ARB, aspirin, and Statin use
was not associated with adiponectin levels in the popula-
tion as a whole. Adiponectin levels were not correlated to
diabetes status or estimated GFR. Though adiponectin
levels were not correlated with BMI in either ethnic
Table 1 Clinical and biochemical characteristics of the study subjects (n = 179)
Variable Latino (n = 119) Non-Latino white (n = 60)
Men (n = 38) Women (n = 81) Men (n = 21) Women (n = 39)
Age, yr 60.2 ± 10.2 60.6 ± 10.4 61.7 ± 9.6 63.9 ± 7.5
BMI, kg/m2 32.6 ± 5.4 33.0 ± 6.3 31.3 ± 8.0 34.7 ± 7.6
Waist Circumference, cm 109.9 ± 13.7 a 102.5 ± 15.4 112.0 ± 20.3 109.0 ± 16.0 c
Type 2 Diabetes 57.9% 51.9% 42.9% 35.9%
HOMA-IR 5.3 (3.4-9.2) 4.5 (3.0-6.5) 4.1 (2.0-6.9) 3.7 (2.3-5.6)
Log(HOMA-IR) 1.7 ± 0.7 1.4 ± 0.7 1.2 ± 1.2 1.2 ± 0.9
Fasting Insulin, μU/ml 18 (12-26) 17 (12-23) 16 (8-25) 16 (9-22)
Estimated GFR, ml/min 89.6 ± 30.7 90.7 ± 24.4 83.5 ± 22.0 74.9 ± 23.8 d
Total Cholesterol, mg/dl 171 ± 46.2 181 ± 36.6 182 ± 41.3 192 ± 41.3
Triglycerides, mg/dl 162 (104-241) 159 (120-204) 135 (91-164) 146 (108-207)
LDL, mg/dl 91.9 ± 35.6 95.3 ± 32.7 99.8 ± 32.8 103.3 ± 31.8
HDL, mg/dl 43.4 ± 9.3 b 53.0 ± 12.5 48.0 ± 12.4 55.1 ± 13.9
Systolic BP, mm Hg 141 ± 19.4 144 ± 23.1 141 ± 24.1 139 ± 21.7
hs-CRP, mg/L 2.8 (1.0-5.3) 3.5 (1.7-6.5) 1.8 (0.9-3.7) 3.5 (1.2-8.5)
ACEI or ARB use 68.4% 56.8% 42.9% 53.9%
TZD use 18.4% 14.8% 0% c 7.7%
ASA use 26.3% 30.9% 57.1% c 35.9%
Statin use 63.2% 43.2% 52.4% 56.40%
Total Adiponectin, μg/ml 4.6 (3.8-6.5) b 7.0 (4.9-11.4) 6.0 (5.0-10.6) ac 11.4 (7.3-17.1) d
HMW Adiponectin*, μg/ml 2.3 (1.2-3.7) a 2.8 (1.7-5.0) 2.9 (2.0-3.9) a 4.4 (2.8-7.9) d
Results are Mean ± sd, Median (interquartile range), or % a P < 0.05, b P < 0.01 for comparison by sex within ethnic group c P < 0.05, d P < 0.01 for comparison
by ethnic group within sex.
* HMW adiponectin was available on 36 Latino men, 71 Latino women, 20 white men, 39 white women.
BMI, body mass index; HOMA-IR, homeostasis model assessment insulin resistance index; GFR, glomerular filtration rate; LDL, low density lipoprotein; HDL, high
density lipoprotein, hs-CRP, high-sensitivity C reactive protein; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; TZD,
thiazolidinedione; HMW, high-molecular-weight.
P<0.01 P<0.05
Figure 1 Total adiponectin concentrations in Latinos versus
non-Latino white patients, by gender. Boxes represent median
(line in the middle of the boxes), mean (+ symbol inside boxes), and
interquartile ranges (25th and 75th percentile; top and bottom of
boxes). The error bars are drawn to the values 1.5 times the
interquartile range (IQR) below the 25th percentile and 1.5 × IQR
above the 75th percentile.
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group or in the population as a whole in the bivariate
analyses, we observed a negative association between adi-
ponectin levels and waist circumference in the non-
Latino group but not in the Latino group.
Adiponectin is negatively associated with waist
circumference in non-Latino white men but not in
Latino men
To further explore our observation of an association
between waist circumference and adiponectin in the
white participants but not the Latino group, we used an
interaction term for ethnicity x waist circumference. As
demonstrated by the plotted regression lines of waist cir-
cumference versus adiponectin by ethnicity (Figure 2) we
found that waist circumference was negatively associated
with adiponectin in the non-Latino group, whereas no
association was found between these two variables in the
Latino group (p value for interaction <0.05). When waist
circumference and adiponectin values are plotted by eth-
nicity and gender (Additional file 1: Figure S1), it
becomes apparent that the observed ethnic difference in
the waist circumference and adiponectin association is
driven by the men, with Latino men having low adipo-
nectin regardless of waist circumference. Thus, at any
given waist circumference, adiponectin is lower in Lati-
nos than in non-Latino whites. The only possible excep-
tion to this observation is at the higher waist
circumference measures where the regression lines for
the men cross and men in both ethnic groups have low
adiponectin. The relationship between adiponectin and
BMI (Figure 3; Additional File 2: Figure S2) is similar,
with lower adiponectin in Latinos versus non-Latino
whites at any given BMI.
Latino ethnicity is negatively associated with decreased
adiponectin
In the multivariate analysis examining the relationship
between ethnicity and adiponectin levels (Table 3 and
Additional File 3: Table S1), Latino ethnicity was the
strongest negative predictor of both total (-4.7; 95% CI
-6.7, -2.8; p < 0001) and HMW (-1.8; 95% CI -2.9, -0.8;
p = 0.001) adiponectin, independent of all other variables
included in the model (age, gender, TZD use, Statin use,
estimated GFR, diabetes status, and waist circumference/
BMI).
Table 2 Kendall’s Tau correlations with total and HMW adiponectin
Variable Total Adiponectin HMW Adiponectin
Latino Non-Latino All subjects Latino Non-Latino All subjects
Age in years 0.21c 0.19a 0.21d 0.22c 0.17 0.22d
Female Gender 0.25c 0.27a 0.24d 0.16a 0.23a 0.17b
BMI -0.02 -0.09 -0.04 -0.06 -0.12 -0.08
Waist Circ. -0.03 -0.24b -0.07 -0.05 -0.22a -0.08
Diabetes 0.05 0.07 -0.03 0.05 -0.13 -0.05
Estimated GFR -0.10 0.03 -0.09 -0.12 0.07 -0.09
ACEI or ARB -0.07 0.10 -0.03 -0.07 0.10 -0.03
TZD 0.23b 0.07 0.15a 0.25b 0.16 0.19b
ASA 0.03 -0.21a -0.02 0.07 -0.05 0.06
Statin -0.17a -0.07 -0.11 -0.13 0.03 -0.05
HMW Adiponectin 0.68d 0.62d 0.66d - - -
a p ≤ 0.05.
b p < 0.01.
c p < 0.001.
d p < 0.0001.
HMW, high-molecular-weight; BMI, body mass index; GFR, glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor
blocker; TZD, thiazolidinedione; ASA, acetylsalicylic acid.
Figure 2 Relationship between total adiponectin level and
waist circumference in Latino and non-Latino white patients.
Scatter-plot and predicted regression lines showing the relationship
between total adiponectin and waist circumference by ethnicity.
Data for Latino patients is represented by x symbols and solid line;
for non-Latino patients by circular symbols and dashed line.
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Adiponectin accounts for the observed ethnic-specific
variability in insulin resistance
In order to measure the contribution of adiponectin
levels to ethnic-group differences in insulin resistance,
we performed multivariate linear regression analyses in
the entire cohort, with logHOMA-IR as the outcome
variable (table 4 and Additional File 3: Table S2). Though
Latino ethnicity showed a strong positive association
with logHOMA-IR when ethnicity and confounders (age,
gender, TZD use, statin use, estimated GFR, waist cir-
cumference/BMI) were included in the model (Model 1),
with the addition of total adiponectin level (Model 2), the
association with Latino ethnicity was no longer signifi-
cant. Similarly, including HMW instead of total adipo-
nectin and adjusting for confounders and ethnicity
(Model 3), HMW adiponectin level was inversely asso-
ciated with logHOMA-IR, and the association between
Latino ethnicity and logHOMA-IR was no longer
significant.
Discussion
In the present study, we found decreased total and HMW
adiponectin levels in Latino compared to non-Latino
white patients with CVD risk. Lower adiponectin levels in
the Latino group were independent of BMI and other fac-
tors known to affect adiponectin, and seemed to account
for the increased insulin resistance observed in this group
compared to non-Latino whites. Ethnic group differences
in HMW adiponectin paralleled those observed in total
adiponectin, and there were no differences in HMW/total
adiponectin ratios in the two ethnic groups. We identified
correlates of total and HMW adiponectin levels in the two
ethnic groups, confirming associations of adiponectin
levels with age, gender, adiposity, and thiazolidinedione
use previously reported in majority populations. Though
there was no association between BMI and adiponectin on
univariate analyses, the expected negative association
between these two variables was observed on multivariate
analyses, suggesting a blunting of the relationship due to
Figure 3 Relationship between total adiponectin level and BMI
in Latino and non-Latino white patients. Scatter-plot and
predicted regression lines showing the relationship between total
adiponectin and BMI by ethnicity. Data for Latino patients is
represented by x symbols and solid line; for non-Latino patients by
circular symbols and dashed line.
Table 3 Linear regression analysis: Association between
adiponectin and clinical characteristics
Dependent variable Estimate (95% CI) P
Total adiponectin
Intercept 9.4 (-0.5, 19.3)
Latino -4.5 (-6.4, -2.5) <0.0001
Age (per 5 years) 0.7 (0.2, 1.2) 0.0041
Female Gender 3.7 (1.8, 5.6) 0.0027
TZD use 5.1 (2.2, 8.0) 0.0001
BMI (per 5 kg/m2) -1.0 (-1.5,-0.2) 0.0054
Statin use -2.4 (-4.3,-0.6) 0.0104
Estimated GFR (per ml/min) -0.02 (-0.05, 0.02) 0.41
Diabetes -0.3 (-2.3, 1.7) 0.76
HMW adiponectin
Intercept 4.4 (-1.0, 9.9)
Latino -1.6 (-2.7, -0.5) 0.0047
Age (per 5 years) 0.3 (0.1, 0.6) 0.0122
Female Gender 1.4 (0.3, 2.4) 0.0107
TZD use 2.9 (1.3, 4.5) 0.0007
BMI (per 5 kg/m2) -0.5 (-1.0,-0.15) 0.0083
Statin use -0.9 (-1.9, 0.2) 0.1007
Estimated GFR (per ml/min) -0.008 (-0.03, 0.01) 0.4176
Diabetes -0.5 (-1.6, 0.6) 0.4029
Estimates reflect changes from group mean for total or HMW adiponectin (μg/
ml) (as reflected by the intercept of the regression model) for each predictive
factor.
TZD, thiazolidinedione; BMI, body mass index; GFR, glomerular filtration rate;
HMW, high-molecular-weight.
Table 4 Multivariate linear regression analysis:
Association between logHOMA-IR and BMI, ethnicity, and
adiponectin
Models (outcome = logHOMA-IR) Estimate (95% CI) P
Model 1: R2 = 0.18
Latino 0.34 (0.095, 0.59) 0.0068
Model 2: R2 = 0.24
Latino 0.19 (-0.56, 0.44) 0.1267
Total Adiponectin -0.035 (-0.054, -0.017) 0.0002
Model 3: R2 = 0.27
Latino 0.18 (-0.061, 0.42) 0.1421
HMW Adiponectin -0.092 (-0.13, -0.056) <0.0001
All models controlled for BMI, age, gender, statin use, and eGFR.
logHOMA-IR, log of homeostasis model assessment insulin resistance index;
BMI, body mass index; HMW, high-molecular-weight; eGFR, estimated
glomerular filtration rate.
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the effect of other modulators not corrected for on uni-
variate analysis. None of the factors found to be associated
with adiponectin accounted for ethnic-group differences
in total or HMW adiponectin. Finally, we did not observe
the expected negative association between waist circum-
ference and adiponectin in Latino men, suggesting differ-
ential regulation of adiponectin in this group.
Our findings of decreased adiponectin in Latinos are
similar to those from studies of adiponectin in other
minority ethnic/racial groups, where adiponectin is
lower in minority groups studied compared to white
populations [5,26-28]. Ours is one of the first studies to
explore the relationship between adiponectin and several
potential regulators of adiponectin in Latinos. Though
obesity is known to be associated with decreased adipo-
nectin, differences in adiposity did not explain decreased
adiponectin in the Latino group in our study. Further-
more, none of the other potential regulators tested
accounted for the observed ethnic differences in adipo-
nectin. Therefore, we conclude that decreased adiponec-
tin in Latinos is determined by genetic or environmental
factors we were not able to measure.
Studies on the contribution of adiponectin to differ-
ences in insulin sensitivity in Latinos versus non-Latino
whites are still lacking. Hanley et al reported lower adi-
ponectin levels in African Americans compared to Lati-
nos [31] but comparisons between Latinos and non-
Latino whites were not made in that study. Similar to our
observations in Latinos versus non-Latino whites, the
ethnic difference in adiponectin levels between the Afri-
can American and Latino groups was no longer signifi-
cant when insulin sensitivity was taken into account,
demonstrating a very close association between these two
variables. Contrary to this report, Latasha et al reported
lower adiponectin levels in African American women
compared to white women with similar insulin sensitiv-
ities [32]. Ethnic and racial minority groups (including
Latinos) participating in the Diabetes Prevention Pro-
gram (DPP) study were reported to have lower baseline
adiponectin levels than non-Latino white participants [5].
Though adiponectin levels were negatively associated
with HOMA-IR in the DPP population as a whole, the
association of these two variables was not measured
within each racial/ethnic group, and the contribution of
decreased adiponectin levels to racial/ethnic differences
in insulin sensitivity was not assessed. Our analyses
demonstrate that the variability in adiponectin levels in
Latinos versus non-Latino whites accounts for the differ-
ences in insulin resistance observed in the two groups.
Indo-Asian women have been found to have lower
HMW/total adiponectin ratios than whites, suggesting
an ethnic-specific regulation of adiponectin isoforms
[33]. Contrary to this report however, we found HMW
adiponectin to be decreased to a similar extent as total
adiponectin in Latinos compared to non-Latino whites.
In addition, HMW/total adiponectin ratios did not differ
between the two ethnic groups. This observation sug-
gests the involvement of mechanisms regulating adipo-
nectin production, with sparing of mechanisms involved
in adiponectin multimerization. Consistent with obser-
vations in majority populations [34], HMW adiponectin
was more strongly associated with insulin sensitivity
than total adiponectin in our population. However, both
total and HMW adiponectin levels were associated with
insulin sensitivity, and the ethnic-specific difference in
insulin sensitivity was no longer apparent when either
adiponectin measure was controlled for in our regres-
sion models. To our knowledge, ours is the first study
to compare HMW adiponectin in Latinos and non-
Latino whites and to identify determinants of HMW
adiponectin in Latinos.
While we are not able to establish a causative associa-
tion between adiponectin and insulin action in this
cross-sectional study, multiple studies have shown that
adiponectin has insulin-sensitizing actions (reviewed in
[35]). In addition, multiple prospective studies and a
recent meta-analysis have demonstrated that individuals
with low adiponectin are at higher risk for development
of type 2 diabetes [5,36]. In the DPP study [5] baseline
adiponectin was a strong independent predictor of inci-
dent diabetes in the three treatment groups (lifestyle,
metformin, and placebo), with a hazard ratios of 0.61-
0.79 per 3 microgram/ml higher adiponectin). Thus, our
findings suggest that decreased adiponectin in Latinos
plays a role in the high incidence of insulin resistance
and type 2 diabetes in this population. As in other
populations, the HMW form of adiponectin is a better
determinant of insulin sensitivity than total adiponectin.
However, the observed decrease in adiponectin in the
Latino population is not isoform-specific.
We found an expected negative association between
waist circumference and adiponectin in women from both
ethnic groups, and in the non-Latino white men, but no
correlation between these two variables in the Latino men
group. Though we used waist circumference as a surrogate
measure of visceral adiposity, our findings are consistent
with those of Hanley et al who reported an inverse corre-
lation between visceral adiposity and adiponectin in Afri-
can Americans but not Mexican Americans [31]. These
findings may indicate ethnic differences in adiponectin
regulation. For instance, it is possible that Latino men are
more sensitive to inhibitory visceral cytokines, resulting in
an early plateau of suppressed adiponectin levels at a
lower waist circumference. Alternatively, other (non-visc-
eral) inhibitory factors may have a stronger influence on
adiponectin levels in Latinos.
Our study has several limitations. Our population con-
sisted of mostly older, overweight or obese adults, who
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had a diagnosis of hypertension and one additional risk
factor for CVD. Therefore, our findings may not apply
to a younger, leaner, or healthier population. Also, our
Latino group was largely comprised of Mexican Ameri-
cans, and thus our results may not be generalizable to
other Latino groups. As this was a cross-sectional study,
we cannot determine directionality in the correlations
observed or fully explore the causes of low adiponectin
in Latinos. Additional limitations of the study include
our use of the homeostasis model, a surrogate marker of
insulin sensitivity, rather than a more direct measure
such as a frequently sampled IV glucose tolerance test
or a hyperinsulinemic euglycemic clamp. Finally, we
used waist circumference as an estimation of visceral
adiposity rather than a more direct measurement such
as can be obtained with CT scans.
Conclusions
We report decreased adiponectin levels in Latinos at
increased risk of cardiovascular disease, when compared
to non-Latino whites, independent of adiposity measures.
While our study confirms previously described associa-
tions between adiponectin and age, gender, thiazolidine-
dione use, and adiposity, none of these variables
accounted for the observed ethnic differences in adiponec-
tin levels. Indeed, after controlling for other variables cor-
related to adiponectin, Latino ethnicity remained the
strongest negative predictor of both total and HMW adi-
ponectin levels. In addition, our findings suggest differen-
tial regulation of adiponectin in these two ethnic
populations, with a negative association between waist cir-
cumference and adiponectin observed in women and non-
Latino white men but not in Latino men. The ethnic-spe-
cific differences we have observed could be a reflection of
differences in genetics or in environmental factors such as
diet. Decreased adiponectin in Latinos may contribute to
increased insulin resistance and thereby increased inci-
dence of type 2 diabetes in this population. These findings
suggest that therapeutic interventions that increase adipo-
nectin levels may have a beneficial impact on the preven-
tion of type 2 diabetes in Latinos. Future studies focusing
on the mechanisms for decreased adiponectin in Latinos
and the metabolic consequences of ethnic differences in
adiponectin levels seem warranted.
Additional material
Additional file 1: Figure S1 - Relationship between total adiponectin
level and waist circumference in Latino and non-Latino white men
and women. Scatter-plot and predicted regression lines showing the
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non-Latino white women by red symbols and red line; and for non-Latino
white men by brown symbols and brown line.
Additional file 2: Figure S2 - Relationship between total adiponectin
level and BMI in Latino and non-Latino white men and women.
Scatter-plot and predicted regression lines showing the relationship
between total adiponectin and BMI by ethnicity and gender. Data for
Latino women is represented by blue symbols and blue line; for Latino
men by green symbols and green line, non-Latino white women by red
symbols and red line; and for non-Latino white men by brown symbols
and brown line.
Additional file 3: Table S1 - Linear regression analysis: Association
between adiponectin and clinical characteristics. Table S2 -
Multivariate linear regression analysis: Association between logHOMA-IR
and BMI/waist circumference, ethnicity, and adiponectin.
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